The advent of intravitreal antievascular endothelial growth factor (VEGF) injections marked a
significant turning point for the treatment of neovascular age-related macular degeneration
(AMD), diabetic macular edema (DME), and retinal vein occlusions (RVOs). However,
despite the clear benefits of anti-VEGF treatment, significant unanswered questions in
clinical practice remain. Two of the most pressing challenges are predicting treatment
burden (eg, patients requiring fewer vs. more intravitreal injections) and visual prognosis …